JAMA NetworkRegorafenib, Ipilimumab, and Nivolumab (RIN) for Patients with Microsatellite Stable Colorectal Cancer and Disease Progression with Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial

Immunotherapy combinations with activity in patients with microsatellite stable (MSS) metastatic colorectal cancer are needed, and the recommended phase 2 dose of RIN had a manageable safety profile and an overall response rate of 27.6%, a median progression-free survival of 4 months, and a median overall survival of 20 months in this nonrandomized clinical trial of 39 patients with metastatic colorectal cancer. Patients with no liver metastases received responses (overall response rate, 36.4%; median overall survival not reached).